CTLA 4 News and Research

RSS

Combining epigenetic drugs with immunotherapies may provide additional clinical benefit to cancer patients

Recent data suggest that epigenetic therapies are likely to provide additional clinical benefit to cancer patients when rationally combined with immunotherapeutic drugs, according to a review published in Clinical Cancer Research, a journal of the American Association for Cancer Research.

15 Sep 2015

MD Anderson's Jim Allison named winner of 2015 Lasker-DeBakey Clinical Medical Research Award

For inventing a completely new way to strike cancer by unlocking a shackled immune system attack, Jim Allison, Ph.D., chair of Immunology at The University of Texas MD Anderson Cancer Center, will receive the nation's highest honor for clinical medical research.

9 Sep 2015

AstraZeneca presents lung cancer research data at WCLC 2015

Data will be reported from across AstraZeneca’s industry-leading lung cancer portfolio at the World Conference on Lung Cancer 2015, beginning this weekend in Denver, Colorado.

8 Sep 2015

MTG Biotherapeutics' MTG-201 granted FDA Orphan Drug Designation for malignant mesothelioma treatment

MTG Biotherapeutics, an immuno-oncology company developing novel therapeutics for the treatment of cancer, today announced that the US Food and Drug Administration has granted Orphan Drug Designation for MTG-201, an advanced biologic therapy targeting Dickkopf-3 gene defects in various cancers, for the treatment of malignant mesothelioma.

23 Aug 2015

Ludwig, CRI launch clinical trials to evaluate immunotherapies for treatment of GBM and solid tumors

Ludwig Cancer Research and the Cancer Research Institute have launched clinical trials evaluating an immunotherapy for the treatment of the brain cancer glioblastoma multiforme (GBM), and a combination of immunotherapies for a variety of solid tumors.

8 Jul 2015

Study aims to determine utility of Trovagene's PCM technology for predicting response to cancer immunotherapy

Trovagene, Inc., a developer of cell-free molecular diagnostics, today announced the launch of a study that aims to determine utility of the Company's Precision Cancer Monitoring (PCM) technology for predicting response to treatment in advanced melanoma patients receiving one or a combination of the novel immunotherapy agents Yervoy (ipilumumab), a CTLA-4 inhibitor, and Opdivo (nivolumab), a PD-1 inhibitor.

8 Jul 2015

Regulatory T cells critical for the immune system's ability to fight off future pathogen attacks

Just as militaries need to have trained, experienced soldiers ready for future wars, making sure that the immune system has enough battle-ready T cells on hand is important for fast-acting, more effective vaccines, according to Penn State researchers.

17 Jun 2015

MedImmune, AstraZeneca present encouraging results from new combination-focused immuno-oncology portfolio at ASCO 2015

AstraZeneca and MedImmune, the company’s global biologics research and development arm, today presented encouraging results from their novel combination-focused immuno-oncology portfolio at the American Society of Clinical Oncology (ASCO) Annual Meeting 2015.

2 Jun 2015

Combination of nivolumab and ipilimumab drugs can improve outcomes in patients with advanced melanoma

Treating advanced melanoma patients with either a combination of the immunotherapy drugs nivolumab (Opdivo™) and ipilimumab (Yervoy™) or nivolumab alone significantly increases progression-free survival (PFS) over using ipilimumab alone, according to new findings from researchers at Memorial Sloan Kettering Cancer Center (MSK) simultaneously presented today at the American Society of Clinical Oncology (ASCO) annual meeting and published online in the New England Journal of Medicine (NEJM). Examining specific characteristics of each patient's tumor has also given researchers clearer understanding of which patients should receive the combination.

1 Jun 2015

MD Anderson Cancer Center's Jim Allison to receive Science of Oncology Award at ASCO 2015

The world's leading organization of oncologists will honor Jim Allison, Ph.D., for his pioneering research that led to a new way to treat cancer by unleashing an immune system attack rather than targeting tumors directly.

30 May 2015

Monoclonal antibody nivolumab improves survival rates of melanoma patients

The monoclonal antibody nivolumab has shown promise as a therapeutic agent, particularly by improving the survival rates of melanoma patients. Jeffrey S. Weber, M.D., Ph.D., director of the Donald A. Adam Comprehensive Melanoma Research Center at Moffitt Cancer Center will be presenting data from a retrospective analysis of the safety of nivolumab in 4 ongoing phase I-III studies in melanoma patients at the 2015 American Society of Clinical Oncology Annual Meeting in Chicago.

29 May 2015

MEDI4736 and tremelimumab combination shows acceptable safety, potential efficacy in NSCLC patients

Advanced non-small cell lung cancer (NSCLC) patients have few effective treatment options and low 5-year survival rates. The checkpoint inhibitors MEDI4736 and tremelimumab have both demonstrated acceptable safety and potential efficacy when used as single-agents in several different types of cancer.

29 May 2015

Astellas, Potenza collaborate to develop immuno-oncology therapeutics for patients with certain cancers

Astellas Pharma Inc. and Potenza Therapeutics, Inc., a biotechnology company developing a portfolio of immuno-oncology programs, today announced an exclusive research and development collaboration.

22 Apr 2015

New drug combination shows promise in patients with metastatic melanoma

Once again, researchers at Penn's Abramson Cancer Center have extended the reach of the immune system in the fight against metastatic melanoma, this time by combining the checkpoint inhibitor tremelimumab with an anti-CD40 monoclonal antibody drug.

20 Apr 2015

James Allison to be honored with 2015 Pezcoller Foundation-AACR International Award for Cancer Research

The 2015 Pezcoller Foundation-American Association for Cancer Research (AACR) International Award for Cancer Research will be presented to James P. Allison, PhD, at the AACR Annual Meeting 2015, to be held in Philadelphia, April 18-22.

17 Apr 2015

St. Luke’s Cancer Center offers new Phase II oncolytic viral therapy clinical trial for advanced melanoma

St. Luke’s Cancer Center is a leader in offering clinical trials for patients with melanoma, the most unusual type of skin cancer and also the most deadly. Physicians such as Sanjiv Agarwala, MD, Chief of Medical Oncology and Hematology for St. Luke’s University Health Network and an internationally recognized melanoma specialist, are committed to bringing the most promising studies to the Lehigh Valley.

8 Apr 2015

New pre-clinical, clinical data for IMBRUVICA to be highlighted at AACR Annual Meeting

Pharmacyclics, Inc. today announced that new pre-clinical and clinical data for ibrutinib (IMBRUVICA) will be highlighted at the 2015 American Association for Cancer Research Annual Meeting to be held April 18 – 22, 2015, in Philadelphia, PA.

19 Mar 2015

Researchers discover why only some patients respond to ipilimumab drug

A collaborative team of leaders in the field of cancer immunology from Memorial Sloan Kettering Cancer Center has made a key discovery that advances the understanding of why some patients respond to ipilimumab, an immunotherapy drug, while others do not. MSK was at the forefront of the clinical research that brought this CTLA-4 blocking antibody to melanoma patients.

23 Nov 2014

Researchers identify genetic signatures in melanoma tumors that predict response to immunotherapy

A team led by Ludwig and Memorial Sloan Kettering (MSK) researchers has published a landmark study on the genetic basis of response to a powerful cancer therapy known as immune checkpoint blockade.

21 Nov 2014

Bristol-Myers Squibb, MD Anderson partner to evaluate multiple immunotherapies

Bristol-Myers Squibb Company and The University of Texas MD Anderson Cancer Center today announced a novel clinical research collaboration to evaluate multiple immunotherapies, including Opdivo (nivolumab), Yervoy (ipilimumab) and three early-stage clinical immuno-oncology assets from Bristol-Myers Squibb, as potential treatment options for acute and chronic leukemia as well as other hematologic malignancies.

6 Oct 2014